US.DVA · DaVita

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.289308214241463,
        "turnoverUsdM": 102.42239229360001,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.DVA",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 229.0972,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 4.6,
      "take_profit_price": 252.0945,
      "target_multiplier": 1.9,
      "technical_strength": 1.58,
      "take_profit_percent": 5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.578616428482926,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 59.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 54.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 235.1225,
    "ma50": 216.864,
    "close": 240.09,
    "prevClose": 238.86,
    "avgVolume20": 654025,
    "volumeRatio": 0.65,
    "changePercent": 0.51
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": 0.019750237852531605,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 0.6321779463849083,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.8059420890664784,
      "volat_points": 0,
      "day_range_pct": 0.02007582190138394,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 59.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 26,
        "contribution": 1.3
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 8.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 57.33,
        "contribution": 8.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 19.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 65,
        "contribution": 19.5
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 54.8,
    "details": [
      "基本面分析總分: 1.3/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 8.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 19.5/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 1.3,
      "資金流": 13.2,
      "市場環境": 8.6,
      "情緒分析": 3,
      "技術信號": 19.5,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0,
          "pePoints": 0.4,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0,
          "marginPoints": 0,
          "turnoverUsdM": 102.42239229360001,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DVA",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 17.09
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 701.0184969000002,
                "ma50": 715.0880007999999,
                "name": "QQQ",
                "close": 687.98999,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.6945061500002,
                "ma50": 744.99000356,
                "name": "SPY",
                "close": 747.030029,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.289308214241463,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141063998,
                "url": "https://finnhub.io/api/news?id=59ba127b3f6b9aabeb9639f480050484114f7ca2e9e1b26b621b661cfe2d5e58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita’s modeled fair value has shifted from US$193.71 to US$208.57, signaling a fresh round of updated price targets that investors are watching closely. Recent analyst commentary has taken a mixed but generally constructive tone, with higher targets often linked to DaVita’s growth investments, technology efforts, and focus on patient outcomes. As you read on, you will see how these changing targets fit into the broader DaVita story and what to monitor as the narrative evolves. Analyst Price...",
                "category": "company",
                "datetime": 1785402520,
                "headline": "DaVita (DVA) Stock Sees Fair Value Lift After Analyst Target Increases"
              },
              {
                "id": 141054623,
                "url": "https://finnhub.io/api/news?id=827bfc7ea67d2086982bd64a0484ca1b01c6eb5a356610baf98a6beaae34021b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Xeltis recently secured an additional €20.5 million in funding led by Horizon 3 Healthcare, with DaVita participating to help advance the aXess™ vascular access platform through US trials, regulatory submissions, and European rollout. Alongside this investment, investor attention has intensified around DaVita’s upcoming August 2026 earnings report and its initiatives to expand equitable access to kidney care, including home dialysis and transplant support. With DaVita’s recent returns in...",
                "category": "company",
                "datetime": 1785334142,
                "headline": "How Xeltis Partnership And Kidney Care Initiatives Could Shape DaVita’s (DVA) Long-Term Care Strategy"
              },
              {
                "id": 141050716,
                "url": "https://finnhub.io/api/news?id=acf31ea34dcd802d0fba9bc5526ffc05d8fde53540c7fa0b4510a7d7042515df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "What a time it’s been for DaVita. In the past six months alone, the company’s stock price has increased by a massive 122%, reaching $235.17 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1785305102,
                "headline": "DaVita (DVA): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 141048436,
                "url": "https://finnhub.io/api/news?id=a26cf1e5ebc30162f711d6570899240b9cce07a4f0f5dbe307583db7d2680b59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "In the latest trading session, DaVita HealthCare (DVA) closed at $239.46, marking a +1.33% move from the previous day.",
                "category": "company",
                "datetime": 1785276005,
                "headline": "Why DaVita HealthCare (DVA) Outpaced the Stock Market Today"
              },
              {
                "id": 140995074,
                "url": "https://finnhub.io/api/news?id=2e3a47d91153d28b9b67dd4c029024e3626b28c9ad8c357cea13d3fbe9037847",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Moon Capital Management, LLC, an investment management company, released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 index rebounded in the second quarter, achieving a 9.6% return for the first half of the year, while Moon Capital Management’s equity portfolio gained 4%. AI-related stocks led […]",
                "category": "company",
                "datetime": 1784817203,
                "headline": "Moon Capital Management Exited DaVita (DVA) with 174% total Return"
              },
              {
                "id": 140939305,
                "url": "https://finnhub.io/api/news?id=15ac27ede822ffec0e8dec40701b723d6df00aed02d2c42729aa2a05cacefd43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita HealthCare (DVA) reached $236.97 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.",
                "category": "company",
                "datetime": 1784325607,
                "headline": "DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors"
              },
              {
                "id": 140927466,
                "url": "https://finnhub.io/api/news?id=cc6407477786d13b4c47e5d8d894ec56c9a407f0925131efb1224e8965782f46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $234.01, denoting a +1.04% move from the preceding trading day.",
                "category": "company",
                "datetime": 1784240104,
                "headline": "DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts"
              },
              {
                "id": 140867052,
                "url": "https://finnhub.io/api/news?id=e152ec756aace3bba58f31a5ce7ae17c139c354610a150c1a6ae283a0dae2912",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $232.8, denoting a +1.45% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783720805,
                "headline": "DaVita HealthCare (DVA) Laps the Stock Market: Here's Why"
              }
            ],
            "raw_source": [
              {
                "id": 141079209,
                "url": "https://finnhub.io/api/news?id=a6471e0133a67e636ec4594009b47f90824127b7b349df3ce876842b2945e378",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.",
                "category": "company",
                "datetime": 1785506760,
                "headline": "Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?"
              },
              {
                "id": 141068616,
                "url": "https://finnhub.io/api/news?id=40b44f41e63b7857e9e36a8644fb6508a1c4e9f44f4936c01762e026d58a57b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.",
                "category": "company",
                "datetime": 1785429240,
                "headline": "Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026"
              },
              {
                "id": 141065804,
                "url": "https://finnhub.io/api/news?id=ad7004e4621b9bc43f368316fb6321769b80f6b32bd615999f35db0fec5eb841",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / July 30, 2026 / For U.S. healthcare systems, clinical and financial stability can be achieved when we look beyond treatment options for individual disease states and instead take a more holistic approach that also ...",
                "category": "company",
                "datetime": 1785414900,
                "headline": "Heart, Kidney & Metabolic Care: A Strategic Imperative for Health Systems"
              },
              {
                "id": 141063998,
                "url": "https://finnhub.io/api/news?id=59ba127b3f6b9aabeb9639f480050484114f7ca2e9e1b26b621b661cfe2d5e58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita’s modeled fair value has shifted from US$193.71 to US$208.57, signaling a fresh round of updated price targets that investors are watching closely. Recent analyst commentary has taken a mixed but generally constructive tone, with higher targets often linked to DaVita’s growth investments, technology efforts, and focus on patient outcomes. As you read on, you will see how these changing targets fit into the broader DaVita story and what to monitor as the narrative evolves. Analyst Price...",
                "category": "company",
                "datetime": 1785402520,
                "headline": "DaVita (DVA) Stock Sees Fair Value Lift After Analyst Target Increases"
              },
              {
                "id": 141055863,
                "url": "https://finnhub.io/api/news?id=dc6b208f3d8cb61b19b3c297a8cc56c2951996a4af7af738c66e92cd98982229",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.",
                "category": "company",
                "datetime": 1785337380,
                "headline": "Here's Why You Should Retain DaVita Stock in Your Portfolio for Now"
              },
              {
                "id": 141054623,
                "url": "https://finnhub.io/api/news?id=827bfc7ea67d2086982bd64a0484ca1b01c6eb5a356610baf98a6beaae34021b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Xeltis recently secured an additional €20.5 million in funding led by Horizon 3 Healthcare, with DaVita participating to help advance the aXess™ vascular access platform through US trials, regulatory submissions, and European rollout. Alongside this investment, investor attention has intensified around DaVita’s upcoming August 2026 earnings report and its initiatives to expand equitable access to kidney care, including home dialysis and transplant support. With DaVita’s recent returns in...",
                "category": "company",
                "datetime": 1785334142,
                "headline": "How Xeltis Partnership And Kidney Care Initiatives Could Shape DaVita’s (DVA) Long-Term Care Strategy"
              },
              {
                "id": 141050716,
                "url": "https://finnhub.io/api/news?id=acf31ea34dcd802d0fba9bc5526ffc05d8fde53540c7fa0b4510a7d7042515df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "What a time it’s been for DaVita. In the past six months alone, the company’s stock price has increased by a massive 122%, reaching $235.17 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1785305102,
                "headline": "DaVita (DVA): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 141048436,
                "url": "https://finnhub.io/api/news?id=a26cf1e5ebc30162f711d6570899240b9cce07a4f0f5dbe307583db7d2680b59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "In the latest trading session, DaVita HealthCare (DVA) closed at $239.46, marking a +1.33% move from the previous day.",
                "category": "company",
                "datetime": 1785276005,
                "headline": "Why DaVita HealthCare (DVA) Outpaced the Stock Market Today"
              },
              {
                "id": 141044156,
                "url": "https://finnhub.io/api/news?id=f297ada419289e690b1bfd00b9d05ed5a86cc6985e2e467c145637d2a0a56040",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / July 28, 2026 /Delivering Our Best for Every Patient Advancing equal access for all patients - regardless of demographic or social status - is central to DaVita's unwavering pursuit of a healthier tomorrow. In the ...",
                "category": "company",
                "datetime": 1785249900,
                "headline": "DaVita Community Care Report 2025 : Advancing Healthcare Access for Every Patient"
              },
              {
                "id": 141040721,
                "url": "https://finnhub.io/api/news?id=8534244f2ee1a181c4672eaee541ad645ae4e926018a71676fb9eca7bd7f598a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders Builds on the €50m secured in 2025 and supports Xeltis’ next phase of clinical, regulatory and commercial executionAdditional €20.5m provides the runway to finalize the ongoing US pivotal trial of aXess™, prepare for FDA submission and US Go-To- Market, fund the European commercial rollout of aXess™, upscale manu",
                "category": "company",
                "datetime": 1785223800,
                "headline": "Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch"
              },
              {
                "id": 141013951,
                "url": "https://finnhub.io/api/news?id=fc11597c6346c291a7b659239030f6981c74d9757be3c5c75a0d6650221c1b9e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323206885/image_1323206885.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DVA",
                "summary": "DaVita (DVA) nears the high end of its historical valuation range, signaling possible overvaluation and mean reversion risk—monitor levels and consider...",
                "category": "company",
                "datetime": 1784942311,
                "headline": "Davita: Valuation Is Nearing Resistance Level"
              },
              {
                "id": 140995074,
                "url": "https://finnhub.io/api/news?id=2e3a47d91153d28b9b67dd4c029024e3626b28c9ad8c357cea13d3fbe9037847",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Moon Capital Management, LLC, an investment management company, released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 index rebounded in the second quarter, achieving a 9.6% return for the first half of the year, while Moon Capital Management’s equity portfolio gained 4%. AI-related stocks led […]",
                "category": "company",
                "datetime": 1784817203,
                "headline": "Moon Capital Management Exited DaVita (DVA) with 174% total Return"
              },
              {
                "id": 140976595,
                "url": "https://finnhub.io/api/news?id=89e110550952c9e15b4507d5306b7b721ede492c9613b6d9bbb958f4ccd0fa50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.",
                "category": "company",
                "datetime": 1784667600,
                "headline": "DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call"
              },
              {
                "id": 140970660,
                "url": "https://finnhub.io/api/news?id=a4b627a8b733a40b37e7f7eae0dc8601667f5fa49da3fce75976aa0a5246b6d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
                "category": "company",
                "datetime": 1784636066,
                "headline": "3 S&P 500 Stocks We Think Twice About"
              },
              {
                "id": 140939305,
                "url": "https://finnhub.io/api/news?id=15ac27ede822ffec0e8dec40701b723d6df00aed02d2c42729aa2a05cacefd43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita HealthCare (DVA) reached $236.97 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.",
                "category": "company",
                "datetime": 1784325607,
                "headline": "DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors"
              },
              {
                "id": 140930883,
                "url": "https://finnhub.io/api/news?id=3f3323cac288baf1f5384f9824b7d82f6bb68ee9951ef53984b98c2ce408b41e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
                "category": "company",
                "datetime": 1784286346,
                "headline": "3 Profitable Stocks We Think Twice About"
              },
              {
                "id": 140930419,
                "url": "https://finnhub.io/api/news?id=a635d42d7e9ba844765bebc179c919fed8652abbb81b6c4c6fa8dc3862caa0f9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2224096544/image_2224096544.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DVA",
                "summary": "Unfortunately, DaVita’s growth algorithm has become more challenging. After decades of expansion, total dialysis treatment volume has been roughly flat for the past six years.",
                "category": "company",
                "datetime": 1784270640,
                "headline": "DaVita: Why We Exited Our Position In Q2"
              },
              {
                "id": 140927466,
                "url": "https://finnhub.io/api/news?id=cc6407477786d13b4c47e5d8d894ec56c9a407f0925131efb1224e8965782f46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $234.01, denoting a +1.04% move from the preceding trading day.",
                "category": "company",
                "datetime": 1784240104,
                "headline": "DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts"
              },
              {
                "id": 140910210,
                "url": "https://finnhub.io/api/news?id=e85d3400ce996fa4fa32383d4c6bdf2bc2d18e773a2481aad50735dd6f1f4365",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1421088347/image_1421088347.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DVA",
                "summary": "DaVita Inc. stock doubled on a Q1 '26 beat and court win, but valuation looks stretched vs. fair value. Click for this DVA update and see if it is right for you.",
                "category": "company",
                "datetime": 1784117670,
                "headline": "DaVita: I Believe This Is Overvalued"
              },
              {
                "id": 140910011,
                "url": "https://finnhub.io/api/news?id=2c406dcdc41760e5e4c2dd9ff5258672503d1236f6da41b0c4254f62a8287caf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita is entering earnings with strong momentum as investors look for another quarter of solid execution.",
                "category": "company",
                "datetime": 1784104257,
                "headline": "What You Need To Know Ahead of DaVita’s Earnings Release"
              },
              {
                "id": 140896094,
                "url": "https://finnhub.io/api/news?id=444721f26be6039adde19cf99644ba828e3405f2b1686dc7955fe51c77e2b8c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1784026511,
                "headline": "3 Unpopular Stocks Walking a Fine Line"
              },
              {
                "id": 140901238,
                "url": "https://finnhub.io/api/news?id=426851a614c229f3f5ec69a0f8e9914da95a173361434696e2a5dc5e78e2433e",
                "image": "",
                "source": "Benzinga",
                "related": "DVA",
                "summary": "Truist Securities  analyst David Macdonald   maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $205 to $250.",
                "category": "company",
                "datetime": 1784021419,
                "headline": "Truist Securities Maintains Hold on DaVita, Raises Price Target to $250"
              },
              {
                "id": 140867052,
                "url": "https://finnhub.io/api/news?id=e152ec756aace3bba58f31a5ce7ae17c139c354610a150c1a6ae283a0dae2912",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $232.8, denoting a +1.45% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783720805,
                "headline": "DaVita HealthCare (DVA) Laps the Stock Market: Here's Why"
              },
              {
                "id": 140866550,
                "url": "https://finnhub.io/api/news?id=db82d130dbc51f82b030b324b1ab99cdfdd3268da58c3354be593dca905cfbf7",
                "image": "",
                "source": "Benzinga",
                "related": "DVA",
                "summary": "UBS  analyst A.J. Rice   maintains DaVita (NYSE:DVA) with a Buy and raises the price target from $235 to $270.",
                "category": "company",
                "datetime": 1783689348,
                "headline": "UBS Maintains Buy on DaVita, Raises Price Target to $270"
              },
              {
                "id": 140856580,
                "url": "https://finnhub.io/api/news?id=5e0cdd5c3b45088f22d617c0e07c5e83b921b663854de12c8600bb3629ee0f5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "Don't underestimate Ted Weschler's role in the post-Buffett era.",
                "category": "company",
                "datetime": 1783637400,
                "headline": "Everyone Is Watching Greg Abel. But Another Berkshire Hathaway Stock Picker Is Quietly Winning in 2026."
              },
              {
                "id": 140852002,
                "url": "https://finnhub.io/api/news?id=1a61697a3ce4b5e855140a4d96c7b4924aa1f8c7d125fea6d9206353edcbbb83",
                "image": "",
                "source": "Benzinga",
                "related": "DVA",
                "summary": "Barclays  analyst Andrew Mok   maintains DaVita (NYSE:DVA) with a Equal-Weight and raises the price target from $194 to $218.",
                "category": "company",
                "datetime": 1783589536,
                "headline": "Barclays Maintains Equal-Weight on DaVita, Raises Price Target to $218"
              },
              {
                "id": 140846456,
                "url": "https://finnhub.io/api/news?id=c38bcca38ca8675078b3be3b4842da8d201fbc3572b18e0e85e9d24128177a42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita HealthCare (DVA) reached $230.72 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.",
                "category": "company",
                "datetime": 1783548905,
                "headline": "DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights"
              },
              {
                "id": 140804348,
                "url": "https://finnhub.io/api/news?id=6527c9645aa5d0ae7ce2b8aba19c821b75610b3af29ca6ebc9a05c8dcc17e770",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DVA",
                "summary": "DaVita stock has delivered a 126.1% return over the past three years, yet valuation checks send mixed signals, with a Discounted Cash Flow (DCF) estimate pointing to a premium while market multiples suggest the shares may still be on the cheap side. DaVita's 126.1% three year return highlights how strongly the stock has rewarded investors who stayed invested over a multi year horizon. Expansion of DaVita's AI driven Integrated Kidney Care platform can support expectations for future cash...",
                "category": "company",
                "datetime": 1783135172,
                "headline": "DaVita (DVA) Stock Could Be 19% Overvalued Despite Strong Q1 Results"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 28,
            "discarded_article_count": 18
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 19.5,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.4,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.4,
            "vcp_reason": "波幅收縮(15.7%→6%)；量縮(v10/v30=0.78)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 757450,
              "down_days": 3,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 591270,
              "avg_vol_20": 674810,
              "avg_vol_30": 757450,
              "range_pct_10": 0.06035241051859575,
              "range_pct_20": 0.08388521111058711,
              "range_pct_30": 0.1567745454916831,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7806059805927784,
              "dist_to_20d_high": 0.0179967026055584,
              "down_shrink_days": 2,
              "breakout_level_20d": 244.49001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.3849630712008503
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.289308214241463,
              "turnoverUsdM": 102.42239229360001,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.DVA",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 229.0972,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 4.6,
            "take_profit_price": 252.0945,
            "target_multiplier": 1.9,
            "technical_strength": 1.58,
            "take_profit_percent": 5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.578616428482926,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 5.4964,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.29
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 103.72
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.044
    },
    "kdj": {
      "d": 71.43,
      "j": 67.99,
      "k": 70.28,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 50.58
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 12889800,
      "recentSlope": 254380,
      "previousSlope": -169870
    },
    "rsi": 56.88,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 226.2493,
      "position": "SAR喺價下",
      "distancePct": 5.76,
      "previousTrend": "上升"
    },
    "ma50": 216.864,
    "macd": {
      "macd": 6.006822724494555,
      "trend": "中性偏多",
      "signal": 6.553464682175414,
      "histogram": -0.5466419576808592
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 234.8429,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 37
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.65,
      "score": 2,
      "avgVolume": 654025,
      "currentVolume": 426600
    },
    "derived": {
      "ma20": 235.1225,
      "ma50": 216.864,
      "prevClose": 238.86,
      "avgVolume10": 579360,
      "avgVolume20": 654025,
      "changePercent": 0.51,
      "avgVolumeForScore": 654025
    },
    "ma_cross": {
      "ma20": 235.1225,
      "ma50": 216.864,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 234.8635,
      "prevMa50": 215.9544,
      "spreadPct": 8.42,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 228.9434,
      "upper": 241.3016,
      "position": "上半部"
    },
    "rsi_short": 79.04,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.65
    }
  }
}

{
  "close": 240.09,
  "volume": 426600,
  "changePercent": 0.51
}